## CL: Colgate-Palmolive Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 1.1% below STRENGTH zone (4.0-10.0%); PEG 3.10 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (47% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($77.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 1)

**1. Colgate-Palmolive (India) Ltd drops for fifth straight session**
- Source: Business Standard | 20251229T080805 | Bearish | Relevance: 100%
- Colgate-Palmolive (India) Ltd experienced its fifth consecutive session of decline, with its stock down 0.92% at Rs 2068.1. This drop contributes to a 25.07% tumble over the last year, underperforming both the NIFTY and Nifty FMCG index. The stock's PE ratio is currently 42.84 based on TTM earnings ending September 25.

**2. Colgate-Palmolive India gets ₹267.64 crore tax demand; to challenge order**
- Source: Adgully.com | 20251228T000805 | Neutral | Relevance: 100%
- Colgate-Palmolive (India) Limited has received an Income Tax Assessment Order demanding ₹267.64 crore for FY 2021–22 (AY 2022–23), primarily due to transfer pricing adjustments and disallowance of certain expenses. The company plans to challenge this order by filing an appeal with the Income Tax Appellate Tribunal, asserting that the order currently has no impact on its financials, operations, or business activities. No penalties or operational restrictions were imposed, and the company stated its commitment to legal compliance.

**3. Colgate-Palmolive (CL) Target Raised as Analysts Split on 2026 Staples Outlook**
- Source: Insider Monkey | 20251230T153800 | Neutral | Relevance: 100%
- BofA recently raised its price target for Colgate-Palmolive (NYSE:CL) to $90 from $88, maintaining a Buy rating while expressing caution about consumption growth in the consumer staples sector for 2026. Conversely, Jefferies, while more constructive on the household and personal care space overall due to easing macro pressures, adopted a more reserved outlook for Colgate-Palmolive due to softer expectations for oral care and slowing demand in premium pet products. Colgate-Palmolive itself acknowledges a challenging operating environment marked by consumer uncertainty, tariffs, geopolitics, and high cost inflation, yet remains focused on its 2030 Strategy leveraging strong brands and emerging market exposure.

**4. Colgate-Palmolive Company $CL Shares Sold by Ethic Inc.**
- Source: MarketBeat | 20251230T090750 | Neutral | Relevance: 100%
- Ethic Inc. significantly reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 12.4% in the third quarter of 2025, selling 15,512 shares and holding 109,824 shares valued at $8.78 million. Despite mixed analyst adjustments to price targets, the consensus rating for CL remains a "Moderate Buy" with an average target of $88.81. Colgate-Palmolive also announced a quarterly dividend of $0.52 per share, payable on February 13, 2026, to shareholders of record on January 21, 2026, representing a 2.6% yield.

**5. Abacus FCF Advisors LLC Acquires 22,105 Shares of Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251230T081806 | Somewhat-Bullish | Relevance: 100%
- Abacus FCF Advisors LLC has increased its stake in Colgate-Palmolive by 11.0% in Q3, purchasing an additional 22,105 shares to own a total of 223,175 shares valued at $17.84 million. This move makes Colgate-Palmolive the 12th largest position in Abacus FCF Advisors' portfolio, representing approximately 2.4% of its total holdings. Other institutional investors also increased their positions, and analysts maintain a "Moderate Buy" rating with an average target price of $88.81.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $88 | $87 | +1% |
| 2025-12-11 | Argus Research | $0 | $0 | 0% |
| 2025-12-09 | RBC Capital | $88 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | main | Overweight |
| 2025-12-11 | Argus Research | down | Hold |
| 2025-12-09 | RBC Capital | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.2%)
- Blackrock Inc.: 8.6% (+0.5%)
- State Street Corpora: 6.0% (+0.2%)
- Price (T.Rowe) Assoc: 4.0% (-11.5%)
- Geode Capital Manage: 2.7% (+4.1%)

### Key Risks

1. Valuation stretched: PEG 3.1x requires aggressive growth execution.
2. Long-term trend broken: trading 6.8% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.10 signals overvaluation risk, limited margin of safety. Forward P/E 20.7x stretched relative to 5% growth. Quality metrics strong (ROE 294%, ROA 15%). Balance sheet: $1.1B free cash flow. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $64.3B |
| Beta | 0.29 |
| 52W Range | $74.55 - $100.18 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.10 |
| Forward P/E | 20.7 |
| Current P/E | 21.8 |
| YoY Growth | 5.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 1.1% (minimal 5-day change). Below STRENGTH zone by 2.9pp (needs >4.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Below SMA200 (0.93x), long-term trend not supportive. RSI neutral at 53. Volume at 47% of 20MA suggests lack of conviction. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.07% (CS: 67) | Neutral |
| RSI_14 | 53.3 | Neutral |
| MACD Histogram | 0.15 | Bullish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.014x | Above |
| vs SMA200 | 0.932x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $79.53
- **Stop Loss:** $77.09 (3.1% risk)
- **Target:** $81.97 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 450
- **Position Value:** $35,788.50
- **Portfolio %:** 35.79%
- **Risk Dollars:** $1,100.00
- **Risk Per Trade:** 1.10%
- **Modifiers:** L1 110% | L2 100% | Combined 1.10x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-01-30 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.89 | $0.91 | +2.4% |
| 2025Q2 | $0.89 | $0.92 | +2.8% |
| 2025Q1 | $0.86 | $0.91 | +6.1% |
| 2024Q4 | $0.89 | $0.91 | +2.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*